Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Helius Medical Technologies (NASDAQ: HSDT) has secured reimbursement approval from United Healthcare for its Portable Neuromodulation Stimulator (PoNS®) Device, making it the second major healthcare provider after Anthem to offer coverage. The approved reimbursement amount totals $18,100, which includes patient co-payment and represents the adjusted list price for out-of-network status.
The PoNS Device is designed to improve balance and gait deficits while reducing fall risk. This development marks a significant milestone in Helius's strategy to expand patient access through commercial payor coverage and third-party reimbursement, particularly benefiting MS patients.
Helius Medical Technologies has announced a 1-for-15 reverse stock split of its Class A common stock, effective May 1, 2025. The split was approved by stockholders on April 21, 2025, allowing a ratio range of 1-for-2 to 1-for-30 to maintain Nasdaq listing compliance.
Starting May 2, 2025, the company's stock will trade on a split-adjusted basis under the same symbol "HSDT" on the Nasdaq Capital Market. The reverse split will reduce outstanding shares from approximately 7.9 million to 0.5 million, while maintaining the authorized share count at 150 million.
Key changes include:
- Every 15 shares will convert to one share
- $0.001 par value remains unchanged
- Fractional shares will be rounded down with cash compensation
- New CUSIP number: 42328V 884
- Proportional adjustments to stock options and warrants
Helius Medical Technologies (NASDAQ:HSDT) has announced the establishment of Revelation Neuro, a wholly-owned private subsidiary focused on developing non-implantable AI-powered Brain Computer Interface (BCI) technology. The subsidiary will leverage Helius' existing IP portfolio and extensive data warehouse for AI algorithm development.
The new venture aims to create a personalized neurorehabilitation solution using translingual stimulation without implantation. Revelation Neuro will utilize Helius' dataset of over 5 years of movement dysfunction clinical evidence from 400+ subjects as the foundation for AI algorithm development. The technology focuses initially on motor function rehabilitation, with potential future applications in cognitive deficit, mood, and behavior disorders.
While Helius will assign its newly developed IP and license existing IP to Revelation Neuro, the company does not plan to invest significant additional capital. Instead, the subsidiary is expected to be financed through third-party outside sources, building upon the $70 million already invested in neuromodulation technology development.
Helius Medical Technologies (HSDT) has achieved a significant milestone with its first reimbursement from a major healthcare provider for its Portable Neuromodulation Stimulator (PoNS®) Device. Anthem Blue Cross Blue Shield approved the claim at an out-of-network adjusted list price.
The reimbursement payment, including patient co-payment, amounted to $15,420 for the PoNS controller and mouthpiece. This out-of-network total lump sum payment, typically 30-40% below in-network contracted rates, establishes a important benchmark for future negotiations with major commercial insurance carriers.
The company views this development as validation of PoNS's therapeutic benefit and economic value for payers, particularly significant as Helius appeals current CMS payment rates.
Helius Medical Technologies (NASDAQ:HSDT) has announced positive results from their PoNS Therapeutic Experience Program (PoNSTEP) study for multiple sclerosis (MS) patients. The study demonstrated significant long-term benefits of PoNS Therapy on gait deficit improvement.
The study involved 43 MS patients who underwent 14 weeks of physical rehabilitation with PoNS Therapy, including 2 weeks in clinic (Phase 1) and 12 weeks at home (Phase 2), followed by a 6-month observation period (Phase 3). Of 41 patients who started, 38 completed the study.
Key findings include a statistically significant total mean improvement of 5.00 points in Dynamic Gait Index (DGI) at week 14. Phase 2 showed 71% therapy adherence with a linear association between adherence and improvement. Notably, participants with ≥85% adherence improved by mean 3.7 points compared to 2.0 points for those with lower adherence. At 6-months post-treatment, only 1 of 28 reassessed participants showed ≥30% decline in DGI.
Helius Medical Technologies (NASDAQ:HSDT) has announced agreements with existing warrant holders to exercise warrants for 4,971,110 shares at a reduced price of $0.751 per share, expecting to generate approximately $3.7 million in gross proceeds. In exchange, the company will issue new warrants in a private placement.
The new warrants will be exercisable for up to 6,213,888 shares at $0.751 per share, subject to stockholder approval. Of these, 3,728,333 warrants will be exercisable for five years and 2,485,555 for two years after stockholder approval. Roth Capital Partners is acting as financial advisor for this transaction.
The company plans to file a resale registration statement with the SEC to register the shares underlying the new warrants. The existing warrant shares are already registered under Form S-1.